<DOC>
	<DOCNO>NCT01078701</DOCNO>
	<brief_summary>The purpose phase IIa trial evaluate immunogenicity single dose GHB11L1 administer liquid nasal spray vaccination influenza A ( H1N1 ) virus . This study also perform assess safety , tolerability pharmacokinetics ( shed ) single dose GHB11L1 administer liquid nasal spray .</brief_summary>
	<brief_title>Dose Finding Study Single Dose GHB11L1 Healthy Adults</brief_title>
	<detailed_description>GHB11L1 intend provide novel vaccination influenza virus infection . 48 healthy volunteer include phase IIa study investigate three dose level . 16 subject randomise ratio 3:1 GHB11L1 placebo . Healthy male volunteer , 18-50 year age seronegative respect apply virus antigen ( antibody titer &lt; 1:10 detect ) randomise . GHB11L1 administer day 1 . Follow-up visit perform day 2 , 8 29 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy male volunteer , 1850 year Seronegative H1N1 ( Influenza A/Brisbane/59/07 antibody titres &lt; 1:10 detect haemagglutination inhibition assay ) Written inform consent participate study Acute febrile illness ( &gt; 37.0°C ) Signs acute chronic upper low tract respiratory illness ( sneeze , cough , tonsillitis , otitis etc . ) History severe atopy Seasonal influenza vaccination 2007/2008 and/or late season and/or pandemic influenza vaccination time Known increase tendency nose bleed Volunteers clinically relevant abnormal paranasal anatomy Volunteers clinically relevant abnormal laboratory value Simultaneous treatment immunosuppressive drug incl . Corticosteroids ( ≥2 week ) within 4 week prior study medication application Clinically relevant history renal , hepatic , GI , cardiovascular , haematological , skin , endocrine , neurological immunological disease History leukaemia cancer HIV Hepatitis B C seropositivity Volunteers underwent rhino sinus surgery , surgery another traumatic injury nose within 30 day prior application study medication Volunteers receive antiviral drug , treatment immunoglobulin blood transfusion , investigational drug within four week prior study medication application Volunteers receive antiinflammatory drug 2 day prior study medication application Volunteers likely cope requirement study significant physical mental condition may interfere completion study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>live attenuate flu vaccine</keyword>
	<keyword>Influenza A ( H1N1 )</keyword>
	<keyword>intranasal application</keyword>
	<keyword>replication-deficient influenza virus</keyword>
</DOC>